Assessment of background levels of autoantibodies as a prognostic marker for severe SARS-CoV-2 infection
Keywords:COVID-19, Current or ex-smokers, Lung cancer, Mortality prediction, Serum biomarkers
Background: Patients with more severe forms of SARS-CoV-2 exhibit activation of immunological cascades. Participants (current or ex-smokers with at least 20 years pack history) in a trial (Early Diagnosis of Lung Cancer, Scotland [ECLS]) of autoantibody detection to predict lung cancer risk had seven autoantibodies measured 5 years before the pandemic. This study compared the response to Covid infection in study participants who tested positive and negative to antibodies to tumour-associated antigens: p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2.
Methods: Autoantibody data from the ECLS study was deterministically linked to the EAVE II database, a national, real-time prospective cohort using Scotland’s health data infrastructure, to describe the epidemiology of SARS-CoV-2 infection, patterns of healthcare use and outcomes. The strength of associations was explored using a network algorithm for exact contingency table significance testing by permutation.
Results: There were no significant differences discerned between SARS-CoV-2 test results and EarlyCDT-Lung test results (p = 0.734). An additional analysis of intensive care unit (ICU) admissions detected no significant differences between those who tested positive and negative. Subgroup analyses showed no difference in COVID-19 positivity or death rates amongst those diagnosed with chronic obstructive pulmonary disease (COPD) with positive and negative EarlyCDT results.
Conclusions: This hypothesis-generating study demonstrated no clinically valuable or statistically significant associations between EarlyCDT positivity in 2013-15 and the likelihood of SARS-CoV-2 positivity in 2020, ICU admission or death in all participants (current or ex-smokers with at least 20 years pack history) or in those with COPD or lung cancer.
Jamal M, Bangash HI, Habiba M, et al. Immune dysregulation and system pathology in COVID-19. Virulence. 2021;12(1):918-936. https://doi.org/10.1080/21505594.2021.1898790 PMID: 33757410
Geretti AM, Stockdale AJ, Kelly SH, et al. Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study. Clin Infect Dis. 2021 Oct 23:ciaa1605. https://doi.org/10.1093/cid/ciaa1605 PMID: 33095853
Chang SH, Minn D, Kim YK. Autoantibodies in moderate and critical cases of COVID-19. Clin Transl Sci. 2021;14(5):1625-1626. https://doi.org/10.1111/cts.13036 PMID:33934534
Chauvineau-Grenier A, Bastard P, Servajean A, et al. Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital. J Clin Immunol. 2022 Apr;42(3):459-470. https://doi.org/10.1007/s10875-021-01203-3. PMID: 35083626
Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci. 2021;14(2):502-508. https://doi.org/10.1111/cts.12908PMID:32989903
Widjaja G, Turki Jalil A, Sulaiman Rahman H, et al. Humoral immune mechanisms involved in protective and pathological immunity during COVID-19. Hum Immunol. 2021 Jul 1:S0198-8859(21)00174-9. https://doi.org/10.1016/j.humimm.2021.06.011. PMID: 34229864
Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection. https://doi.org/10.1016/S1556-0864(15)30352-X PMID:17409910
Chu GCW, Lazare K, Sullivan F. Serum and blood based biomarkers for lung cancer screening: a systematic review. BMC Cancer. 2018;18(1):181. https://doi.org/10.1186/s12885-018-4024-3PMID:29439651
Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005;4(4):1123-1133. https://doi.org/10.1021/pr0500814 PMID:16083262
Lam S, Boyle P, Healey GF, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4(7):1126-1134. https://doi.org/10.1158/1940-6207.CAPR-10-0328 PMID:21733826
Murray A, Chapman CJ, Healey G, et al. Technical validation of an autoantibody test for lung cancer. Ann Oncol. 2010;21(8):1687-1693. https://doi.org/10.1093/annonc/mdp606PMID:20124350
Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001 Jul;93(14):1054-1061. https://doi.org/10.1093/jnci/93.14.1054 PMID: 1145986
Sullivan FM, Mair FS, Anderson W, et al; Early Diagnosis of Lung Cancer Scotland (ECLS) Team. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. Eur Respir J. 2020;57:2000670. https://doi.org/10.1183/13993003.00670-2020 PMID:32732334
Sullivan FM, Farmer E, Mair FS, et al. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial. BMC Cancer. 2017;17(1):187. https://doi.org/10.1186/s12885-017-3175-y PMID:28284200
Kendrick S, Clarke J. The Scottish record linkage system. Health Bull (Edinb). 1993;51(2):72-79. PMID:8514493
Mulholland RH, Vasileiou E, Simpson CR, et al. Cohort profile: early pandemic evaluation and enhanced surveillance of COVID-19 (EAVE II) database. Int J Epidemiol. 2021;50(4):1064-1065. https://doi.org/10.1093/ije/dyab028 PMID:34089614
National Health Service (NHS). Community Health Index (CHI). Available online: https://datadictionary.nhs.uk/attributes/community_health_index_number.html (last accessed August 2021).
Data Service, Data Team Linkage Options, University of Dundee https://www.dundee.ac.uk/hic/datalinkageservice/ (last accessed April 2022).
Muratori P, Lenzi M, Muratori L, Granito A. Antinuclear antibodies in COVID 19. Clin Transl Sci. 2021;14(5):1627-1628. https://doi.org/10.1111/cts.13026 PMID:33932091
Qi X, Liu C, Jiang Z, et al. Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. J Hepatol. 2020;73(2):455-458. https://doi.org/10.1016/j.jhep.2020.04.010 PMID:32305291
Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a biological predictor of outcomes in COVID-19 patients: a nationwide cohort study. Cancers (Basel). 2021;13(3):471. https://doi.org/10.3390/cancers13030471 PMID: 33530509
Martha JW, Wibowo A, Pranata R. Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: a systematic review and meta-analysis. Postgrad Med J. 2021 Jan 15:postgradmedj-2020-139542. https://doi.org/10.1136/postgradmedj-2020-139542 PMID: 33452143
Poudel A, Poudel Y, Adhikari A, et al. D-dimer as a biomarker for assessment of COVID-19 prognosis: d-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One. 2021;16(8):e0256744. https://doi.org/10.1371/journal.pone.0256744 PMID:34437642
Shen B, Yi X, Sun Y, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182(1):59-72.e15. https://doi.org/10.1016/j.cell.2020.05.032PMID:32492406
Yitbarek GY, Walle Ayehu G, Asnakew S, et al. The role of C-reactive protein in predicting the severity of COVID-19 disease: a systematic review. SAGE Open Med. 2021;9:20503121211050755. https://doi.org/10.1177/20503121211050755 PMID:34659766
Tong-Minh K, van der Does Y, Engelen S, et al. High procalcitonin levels associated with increased intensive care unit admission and mortality in patients with a COVID-19 infection in the emergency department. BMC Infect Dis. 2022;22(1):165. https://doi.org/10.1186/s12879-022-07144-5 PMID:35189826
Kaushal K, Kaur H, Sarma P, et al. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. J Crit Care. 2022 Feb;67:172-181. https://doi.org/10.1016/j.jcrc.2021.09.023 PMID: 34808527
How to Cite
Copyright (c) 2022 Frank M. Sullivan, Dr Agnes Tello, Petra Rauchhaus, Virginia Hernandez Santiago, Fergus Daly
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to Journal of Circulating Biomarkers agree to publish their articles under the Creative Common Attribution Non Commercial 4.0 (CC-BY-NC 4.0) license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.